Malaria is a parasitic disease that causes one million deaths a year. The most severe species, Plasmodium falciparum is able to infect human red blood cells (erythrocytes) irrespective of maturity. Before the emergence of drug-resistance in the 1960s, chloroquine was a life-saving tool for controlling of malaria due to its efficacy, low toxicity and affordability. Misuse of the drug has given rise to resistant strains, which have since proliferated across the globe.
As part of ongoing work on labelling and studying the mode-of-actions of clinically-used antimalarial agents, BioLynx Technologies now presents a series of fluorescent-tagged chloroquine analogues: LynxTag-CQ™BLUE and LynxTag-CQ ™GREEN.
1. Easy to use. Live cell visualization using Fluorescent-Tagged Drugs (FTDs) requires neither specialized nor complex equipment, or reagents other than flow cytometry or fluorescence microscopy setups, which would allow even small-scale laboratories to utilize this technology
2. Enables in vitro visualization of drug localization in live cells. For drug resistance mechanism studies, it is important to be able to track and record the movement of drugs within live cells.
3. Does not alter the effectiveness of the drug. These FTDs have been shown not to interfere with cellular pathways in the host cell, which results in more precise and useful information pertaining to drug-cell interactions.